Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Article in English | MEDLINE | ID: mdl-38900843

ABSTRACT

PURPOSE OF REVIEW: The ocular surface is prone to inflammation due to exposure to environmental irritants and pathogens. Inflammasomes are intracellular, multiprotein complexes that communicate potentially dangerous signals to the immune system. The identification of inflammasomes in various inflammatory ocular surface conditions can aid in the development of therapeutics to treat these chronic inflammatory conditions. RECENT FINDINGS: Several inflammasomes have been associated with ocular surface disorders including dry eye disease, keratitis, and allergies. Mechanisms for activation of these inflammasomes with regards to specific disorders have been explored in models to aid in the development of targeted treatments. SUMMARY: Research efforts continue to characterize the types of inflammasomes and activators of these in inflammatory ocular surface conditions. Various therapies targeting specific inflammasome types or pyroptosis are being tested preclinically to assess effects on decreasing the associated chronic inflammation.

2.
BMC Med ; 22(1): 149, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38581003

ABSTRACT

BACKGROUND: Various studies have demonstrated gender disparities in workplace settings and the need for further intervention. This study identifies and examines evidence from randomized controlled trials (RCTs) on interventions examining gender equity in workplace or volunteer settings. An additional aim was to determine whether interventions considered intersection of gender and other variables, including PROGRESS-Plus equity variables (e.g., race/ethnicity). METHODS: Scoping review conducted using the JBI guide. Literature was searched in MEDLINE, Embase, PsycINFO, CINAHL, Web of Science, ERIC, Index to Legal Periodicals and Books, PAIS Index, Policy Index File, and the Canadian Business & Current Affairs Database from inception to May 9, 2022, with an updated search on October 17, 2022. Results were reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension to scoping reviews (PRISMA-ScR), Sex and Gender Equity in Research (SAGER) guidance, Strengthening the Integration of Intersectionality Theory in Health Inequality Analysis (SIITHIA) checklist, and Guidance for Reporting Involvement of Patients and the Public (GRIPP) version 2 checklist. All employment or volunteer sectors settings were included. Included interventions were designed to promote workplace gender equity that targeted: (a) individuals, (b) organizations, or (c) systems. Any comparator was eligible. Outcomes measures included any gender equity related outcome, whether it was measuring intervention effectiveness (as defined by included studies) or implementation. Data analyses were descriptive in nature. As recommended in the JBI guide to scoping reviews, only high-level content analysis was conducted to categorize the interventions, which were reported using a previously published framework. RESULTS: We screened 8855 citations, 803 grey literature sources, and 663 full-text articles, resulting in 24 unique RCTs and one companion report that met inclusion criteria. Most studies (91.7%) failed to report how they established sex or gender. Twenty-three of 24 (95.8%) studies reported at least one PROGRESS-Plus variable: typically sex or gender or occupation. Two RCTs (8.3%) identified a non-binary gender identity. None of the RCTs reported on relationships between gender and other characteristics (e.g., disability, age, etc.). We identified 24 gender equity promoting interventions in the workplace that were evaluated and categorized into one or more of the following themes: (i) quantifying gender impacts; (ii) behavioural or systemic changes; (iii) career flexibility; (iv) increased visibility, recognition, and representation; (v) creating opportunities for development, mentorship, and sponsorship; and (vi) financial support. Of these interventions, 20/24 (83.3%) had positive conclusion statements for their primary outcomes (e.g., improved academic productivity, increased self-esteem) across heterogeneous outcomes. CONCLUSIONS: There is a paucity of literature on interventions to promote workplace gender equity. While some interventions elicited positive conclusions across a variety of outcomes, standardized outcome measures considering specific contexts and cultures are required. Few PROGRESS-Plus items were reported. Non-binary gender identities and issues related to intersectionality were not adequately considered. Future research should provide consistent and contemporary definitions of gender and sex. TRIAL REGISTRATION: Open Science Framework https://osf.io/x8yae .


Subject(s)
Gender Equity , Workplace , Male , Female , Humans , Canada , Randomized Controlled Trials as Topic
3.
J Immunol ; 198(2): 645-656, 2017 01 15.
Article in English | MEDLINE | ID: mdl-27956527

ABSTRACT

Molecules that are necessary for ocular hypersensitivity reactions include the receptors CCR1 and CCR3; CCL7 is a ligand for these receptors. Therefore, we explored the role of CCL7 in mast cell activity and motility in vitro and investigated the requirement for CCL7 in a murine model of IgE-mediated allergic conjunctivitis. For mast cells treated with IgE and Ag, the presence of CCL7 synergistically enhanced degranulation and calcium influx. CCL7 also induced chemotaxis in mast cells. CCL7-deficient bone marrow-derived mast cells showed decreased degranulation following IgE and Ag treatment compared with wild-type bone marrow-derived mast cells, but there was no difference in degranulation when cells were activated via an IgE-independent pathway. In vivo, CCL7 was upregulated in conjunctival tissue during an OVA-induced allergic response. Notably, the early-phase clinical symptoms in the conjunctiva after OVA challenge were significantly higher in OVA-sensitized wild-type mice than in control challenged wild-type mice; the increase was suppressed in CCL7-deficient mice. In the OVA-induced allergic response, the numbers of conjunctival mast cells were lower in CCL7-deficient mice than in wild-type mice. Our results demonstrate that CCL7 is required for maximal OVA-induced ocular anaphylaxis, mast cell recruitment in vivo, and maximal FcεRI-mediated mast cell activation in vitro. A better understanding of the role of CCL7 in mediating ocular hypersensitivity reactions will provide insights into mast cell function and novel treatments for allergic ocular diseases.


Subject(s)
Chemokine CCL7/immunology , Conjunctivitis, Allergic/immunology , Mast Cells/immunology , Animals , Blotting, Western , Cell Degranulation/immunology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Mice , Mice, Inbred C57BL , Mice, Knockout , Real-Time Polymerase Chain Reaction
4.
Ophthalmic Surg Lasers Imaging Retina ; 46(3): 362-8, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25856824

ABSTRACT

BACKGROUND AND OBJECTIVE: To characterize the cellular, immunological, and inflammatory response to retinal photocoagulation of intense rupture laser lesions as a model of retinal degenerative diseases. MATERIALS AND METHODS: Seven C57BL/6 mice were irradiated using a 532-nm laser to induce 10 retinal burns per eye that ruptured Bruch's membrane. Blood was drawn from the saphenous vein before and 2 months after laser treatment. The serum was run on antigen microarrays with 85 molecular markers associated with retinal degenerative diseases. RESULTS: Rupture laser resulted in dramatic changes in the immunoglobulin reactivity of most inflammatory markers 2 months after laser injury. Approximately two-thirds increased expression and one-third decreased expression. Notable markers that were increased included complement C3, CRP, PKM2, and aldolase. CONCLUSION: Rupture laser injury causes a change in the serum inflammatory markers after 2 months similar to macular degeneration, diabetic retinopathy, and cancer-associated retinopathy. This animal model could be used as a biomarker for disease stage and activity in retinal degenerations.


Subject(s)
Biomarkers/blood , Bruch Membrane/injuries , Disease Models, Animal , Laser Coagulation/adverse effects , Retinal Degeneration/blood , Animals , C-Reactive Protein/metabolism , Complement C3/metabolism , Fructose-Bisphosphate Aldolase/blood , Immunoglobulin G/blood , Inflammation , Mice , Mice, Inbred C57BL , Pyruvate Kinase/blood , Retinal Degeneration/etiology , Retinal Degeneration/pathology , Rupture , Saphenous Vein
5.
Curr Eye Res ; 38(3): 317-30, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23281793

ABSTRACT

The prevalence of allergy is rising globally at a very significant rate, which is currently at 20-40% of individuals in westernized nations. In the eye, allergic conditions can take on the acute form such as in seasonal and perennial allergic conjunctivitis, or a more severe and debilitating chronic form such as in vernal and atopic keratoconjunctivitis. Indeed, some key aspects of allergic eye disease pathophysiology are understood, such as the role of mast cells in the acute allergic reaction, and the contribution of eosinophils in late-onset and chronic allergy. However, recent developments in animal models and clinical studies have uncovered new and important roles for previously underappreciated players, including chemokine receptors on ocular surface dendritic cells such as CCR7, the contribution of conjunctival epithelium to immunity, histamine and leukotriene receptors on conjunctival goblet cells and a role for mast cells in late-onset manifestations. Furthermore, recent work in animal models has delineated the contribution of IL-4 in the increased incidence of corneal graft rejection in hosts with allergic conjunctivitis. Recent studies such as these mean that conventional paradigms and concepts should be revisited. The aim of this review is to highlight some of the most recent advances and insights on newly appreciated players in the pathogenesis of allergic eye disease.


Subject(s)
Conjunctivitis, Allergic/etiology , Conjunctivitis, Allergic/epidemiology , Conjunctivitis, Allergic/physiopathology , Corneal Transplantation , Dendritic Cells/physiology , Global Health , Goblet Cells/physiology , Humans , Mast Cells/physiology
6.
Exp Mol Pathol ; 93(3): 408-15, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23000510

ABSTRACT

Mast cells play a key role in immunoglobulin E (IgE)-associated allergic disorders; however, the cellular effects of sensitization remain poorly understood. Using gene microarrays and the multiplexing ELISA method, we examined the effects of sensitization on RBL-CCR1 cell transcription and chemokine/cytokine secretion. Sensitization most prominently increased transcription of Trb3, the gene for tribbles homolog 3 (TRB3), and also increased the release of most of the cytokines and chemokines tested. Knockdown of TRB3 via RNAi significantly induced the production of tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), interleukin-6 (IL-6), and the chemokine mast cell protease-1 (MCP-1). TRB3 deficiency also induced IκBα phosphorylation. TRB3 may therefore serve as a negative regulator of pro-inflammatory cytokines and chemokines, controlling the extent of the inflammatory response.


Subject(s)
Immunoglobulin E/immunology , Mast Cells/immunology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Animals , Cell Line, Tumor , Chemokines/biosynthesis , Enzyme-Linked Immunosorbent Assay , Gene Expression , Gene Expression Profiling , Gene Knockdown Techniques , Humans , Mast Cells/metabolism , Mice , Mice, Inbred BALB C , Protein Serine-Threonine Kinases/physiology , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Rats
7.
Br J Ophthalmol ; 96(8): 1132-6, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22694967

ABSTRACT

BACKGROUND/AIMS: Allergic conjunctivitis is characterised by early-phase clinical symptoms and late-phase inflammation in the conjunctiva. The role of different chemokine receptors in allergic conjunctivitis, especially during the early-phase reaction, is still unclear. We investigated the importance of CC chemokine receptor (CCR) 3 in a murine model of IgE-mediated allergic conjunctivitis using CCR3-deficient (CCR3(-/-)) mice. METHODS: Allergic conjunctivitis was initiated in wild-type (WT) and CCR3(-/-) mice by passive transfer of ragweed (RW)-specific IgE, followed by topical challenge with RW in eye drops. Early-phase reactions including clinical symptoms and vascular leakage, as well as late-phase eosinophil infiltration of the conjunctiva were evaluated. The expression of mRNAs in the conjunctiva was quantified by real-time PCR analysis. RESULTS: The number of infiltrated eosinophils in the conjunctiva following RW challenge, was significantly higher in RW-IgE-sensitised WT mice compared with those sensitised with phosphate-buffered saline for WT, but this was not observed in similarly treated CCR3(-/-) mice. The early-phase clinical symptoms and vascular leakage were also suppressed in CCR3(-/-) mice. The number of conjunctival mast cells were not different between CCR3(-/-) mice and WT mice, and the mRNAs for FcεRІα and the connective tissue-type mast cell proteases were detected in the conjunctiva of both WT and CCR3(-/-) mice. RW-IgE-sensitised CCR3(-/-) mice displayed significantly reduced expression of CCL2, CCL3, and IL-6 compared with WT mice. CONCLUSIONS: These results demonstrate a direct contribution of CCR3 to both the early-phase reaction and late-phase inflammation during ocular allergy.


Subject(s)
Conjunctivitis, Allergic/immunology , Disease Models, Animal , Eosinophilia/metabolism , Hypersensitivity, Immediate/metabolism , Immunoglobulin E/immunology , Receptors, CCR3/physiology , Ambrosia/immunology , Animals , Eosinophils/cytology , Leukocyte Count , Mice , Mice, Knockout , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction
8.
J Biol Chem ; 287(29): 24516-24, 2012 Jul 13.
Article in English | MEDLINE | ID: mdl-22613718

ABSTRACT

Accumulating evidence points to cross-talk between FcεRI and CC chemokine receptor (CCR)-mediated signaling pathways in mast cells. Here, we propose that vimentin, a protein comprising type III intermediate filament, participates in such cross-talk for CCL2/monocyte chemotactic protein 1 (MCP-1) production in mast cells, which is a mechanism for allergic inflammation. Co-stimulation via FcεRI, using IgE/antigen, and CCR1, using recombinant CCL3/macrophage inflammatory protein-1α (MIP-1α), increased expression of phosphorylated, disassembled, and soluble vimentin in rat basophilic leukemia (RBL)-2H3 cells expressing human CCR1 (RBL-CCR1 cells) and bone marrow-derived murine mast cells, both models of mucosal type mast cells. Furthermore, co-stimulation enhanced production of CCL2 as well as phosphorylation of MAPK. Treating the cells with p38 MAPK inhibitor SB203580, but not with MEK inhibitor PD98058, reduced CCL2 production, suggesting that p38 MAPK, but not ERK1/2, plays a critical role in the chemokine production. Immunoprecipitation analysis showed that vimentin interacts with phosphorylated ERK1/2 and p38 MAPKs in the co-simulated cells. Preventing disassembly of the vimentin by aggregating vimentin filaments using ß,ß'-iminodipropionitrile reduced the interaction of vimentin with phosphorylated MAPKs as well as CCL2 production in the cells. Taken together, disassembled vimentin interacting with phosphorylated p38 MAPK could mediate CCL2 production in mast cells upon FcεRI and CCR1 activation.


Subject(s)
Mast Cells/metabolism , Mitogen-Activated Protein Kinases/metabolism , Receptors, CCR1/metabolism , Receptors, IgG/metabolism , Vimentin/metabolism , Animals , Cell Line , Cell Line, Tumor , Cells, Cultured , Chemokine CCL2/metabolism , Electrophoresis, Gel, Two-Dimensional , Enzyme-Linked Immunosorbent Assay , Humans , Imidazoles/pharmacology , Immunoprecipitation , Mast Cells/drug effects , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Organic Chemicals/pharmacology , Phosphorylation , Protein Binding , Pyridines/pharmacology , Rats , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
9.
Exp Mol Pathol ; 93(2): 193-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22465421

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial counties. Recent findings indicate that the autoimmunity is involved in the pathogenesis of the disease. However, there is no autoantibody biomarker applied in a clinical setting for diagnosis and prognosis of AMD. In order to reveal retinal antigens targeted by serum IgG from AMD patients, mouse retinal tissue proteins were separated by 2-dimensional electrophoresis and the proteins in the immunoblots that were specific for dry and wet AMD patients IgG were identified by LC-MS/MS. Retinol-binding protein 3 and aldolase C (ALDOC) were mainly recognized by IgG form wet AMD patients. Pyruvate kinase M2 (PKM2) was targeted by both dry and wet AMD and level of anti-PKM2 IgG antibody was correlated best with the stage of AMD. Expression of ALDOC and PKM2 was decreased in mouse retina from aging whereas PKM2 deposit on RPE was increased in aged mice. Our data demonstrate that sera of AMD patients contain autoantibodies against retinal proteins and anti-PKM2 IgG serves as a biomarker for diagnosis and prognosis of AMD. Further investigation of the association of anti-retinal antibody level with expression level of antigens in retina will be needed to reveal the disease pathogenesis.


Subject(s)
Autoantibodies/blood , Geographic Atrophy/immunology , Retina/immunology , Wet Macular Degeneration/immunology , Aged , Aged, 80 and over , Animals , Autoantibodies/isolation & purification , Autoantigens/immunology , Biomarkers/blood , Female , Fructose-Bisphosphate Aldolase/immunology , Geographic Atrophy/diagnosis , Humans , Immunoglobulin G/immunology , Male , Mice , Prognosis , Pyruvate Kinase/immunology , Retinol-Binding Proteins/immunology , Wet Macular Degeneration/diagnosis
10.
Exp Mol Pathol ; 92(3): 267-74, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22417871

ABSTRACT

Mast cell function is a critical component of allergic reactions. Mast cell responses mediated by the high-affinity immunoglobulin E receptor FcεRI can be enhanced by co-activation of additional receptors such as CC chemokine receptor 1 (CCR1). To examine the downstream effects of FcεRI-CCR1 costimulation, rat basophilic leukemia cells stably transfected with CCR1 (RBL-CCR1 cells) were sensitized and activated with antigen and/or the CCR1 ligand CC chemokine ligand (CCL) 3. Gene and protein expression were determined at 3h and 24h post-activation, respectively, using GeneChip and Luminex bead assays. Gene microarray analysis demonstrated that 32 genes were differentially regulated in response to costimulation, as opposed to stimulation with antigen or CCL3 alone. The genes most significantly up-regulated by FcεRI-CCR1 costimulation were Ccl7, Rgs1, Emp1 and RT1-S3. CCL7 protein was also expressed at higher levels 24h after dual receptor activation, although RGS1, EMP1 and RT1-S3 were not. Of the panel of chemokines and cytokines tested, only CCL2, CCL7 and interleukin (IL)-6 were expressed at higher levels following costimulation. IL-6 expression was seen only after FcεRI-CCR1 costimulation, although the amount expressed was very low. CCL7, CCL2 and IL-6 might play roles in mast cell regulation of late-phase allergic responses.


Subject(s)
Gene Expression Profiling , Mast Cells/immunology , Receptors, CCR1/immunology , Receptors, IgE/immunology , Animals , Cell Line, Tumor , Chemokine CCL2/genetics , Chemokine CCL2/immunology , Chemokine CCL2/metabolism , Chemokine CCL7/genetics , Chemokine CCL7/immunology , Chemokine CCL7/metabolism , Chemokines/genetics , Chemokines/immunology , Chemokines/metabolism , Cluster Analysis , Cytokines/genetics , Cytokines/immunology , Cytokines/metabolism , Flow Cytometry , Humans , Immunoblotting , Interleukin-6/genetics , Interleukin-6/immunology , Interleukin-6/metabolism , Mast Cells/metabolism , Oligonucleotide Array Sequence Analysis , Rats , Receptors, CCR1/genetics , Receptors, CCR1/metabolism , Receptors, IgE/genetics , Receptors, IgE/metabolism , Transfection
11.
Exp Mol Pathol ; 92(1): 64-73, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22001380

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial counties. Its pathogenesis is at least partially mediated by immunological factors, including a possible autoimmune response. To date, only a few antibodies have been identified in sera from patients with AMD. In order to reveal an autoantibody profile for AMD and identify biomarkers for progression of this disease, we have performed an antigen microarray analysis of serum samples from patients with AMD and healthy controls. Sera from the AMD groups contained high levels of IgG and IgM autoantibodies to some systemic antigens when compared to the normal group. Targeted antigens included cyclic nucleotide phosphodiesterase, phosphatidylserine (PS) and proliferating cell nuclear antigen. The IgG/IgM ratio for antibodies to PS was notably elevated in the AMD group compared to the normal group, and this ratio correlated best with the stage of AMD patients with an anti-PS ratio greater than the cut-off value had a 44-fold risk for advanced AMD with choroidal neovascularization. PS immunoreactivity was also elevated in AMD retina. Moreover, IgG autoantibodies purified from sera of AMD patients induced more tube formation on choroidal-retinal endothelial cells compared to those of healthy donors. Hence, sera from patients with AMD contain specific autoantibodies which may be used as biomarkers for AMD, and the IgG/M ratio for autoantibodies to PS might allow better monitoring of AMD progression.


Subject(s)
Autoantibodies/blood , Macular Degeneration/immunology , Phosphatidylserines/immunology , Retina/immunology , Retinal Neovascularization/immunology , Aged , Aged, 80 and over , Autoantibodies/immunology , Autoantigens/immunology , Autoimmunity/immunology , Biomarkers/blood , Cluster Analysis , Disease Progression , Endothelial Cells/immunology , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Macular Degeneration/blood , Macular Degeneration/pathology , Male , Middle Aged , Protein Array Analysis , Retina/pathology , Sensitivity and Specificity
12.
Drug Des Devel Ther ; 5: 77-84, 2011 Feb 08.
Article in English | MEDLINE | ID: mdl-21340041

ABSTRACT

BACKGROUND: Antihistamines constitute the first line of therapy for allergic conjunctivitis, and are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they are less effective than some other drugs in relieving delayed symptoms of allergic conjunctivitis. Recent evidence suggests that changes in the conjunctival epithelium may underlie aspects of delayed reactions. In this study we compared two antihistamines, olopatadine and alcaftadine, for their ability to modify epithelial cell changes associated with allergic conjunctivitis at time points selected to reflect late-phase reactions. METHODS: Studies employed a modified conjunctival allergen challenge model. Sensitized mice were challenged with topical allergen with or without drug treatments. Treatment groups were assayed for acute-phase (15 minutes) and delayed-phase (24 hours) responses. Groups were scored for allergy symptoms (redness, itch, tearing, and edema) and for conjunctival mast cell numbers. Delayed-phase groups were also examined for eosinophil numbers and for tight junctional protein expression. RESULTS: Olopatadine-treated and alcaftadine-treated animals had similar efficacy profiles and mast cell numbers, suggesting both were effective at ameliorating symptoms of the acute phase. In contrast, alcaftadine-treated animals had significantly lower conjunctival eosinophil infiltration than either controls or olopatadine-treated animals. Allergen challenge caused a significant decrease in expression of the junctional protein, ZO-1, and this decrease was prevented by alcaftadine but not by olopatadine. CONCLUSION: Alcaftadine displays therapeutic properties beyond its antihistamine action. These include an ability to reduce conjunctival eosinophil recruitment, and a protective effect on epithelial tight junction protein expression.


Subject(s)
Anti-Allergic Agents/pharmacokinetics , Benzazepines/pharmacology , Conjunctivitis, Allergic/drug therapy , Dibenzoxepins/pharmacology , Imidazoles/pharmacology , Animals , Anti-Allergic Agents/administration & dosage , Benzazepines/administration & dosage , Conjunctiva/drug effects , Conjunctiva/metabolism , Dibenzoxepins/administration & dosage , Disease Models, Animal , Eosinophils/drug effects , Eosinophils/metabolism , Epithelium/drug effects , Epithelium/metabolism , Gene Expression Regulation/drug effects , Imidazoles/administration & dosage , Membrane Proteins/genetics , Mice , Mice, Inbred BALB C , Olopatadine Hydrochloride , Phosphoproteins/genetics , Tight Junctions/drug effects , Tight Junctions/metabolism , Time Factors , Zonula Occludens-1 Protein
13.
Br J Ophthalmol ; 94(12): 1662-7, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20805129

ABSTRACT

BACKGROUND: Dendritic cells (DCs) are the most potent antigen-presenting cells involved in initiating the immune response, presenting antigens to T cells and leading to T cell proliferation. In an immature state, DCs lack accessory signals required for T cell stimulation but are highly specialised to capture antigens. Full DC maturation changes the cell surface phenotype and facilitates stimulation of T cell proliferative responses. To examine the degree of DC maturity associated with vernal keratoconjunctivitis (VKC), the authors examined the phenotype and antigen-presentation capability of blood derived DCs from VKC patients and from normal controls. METHODS: Flow cytometry was used to identify the cell surface expression of markers of DC maturity (CD83, CD86, major histocompatibility complex class II) and mixed leucocyte reactions to assess DC induction of T cell proliferation. RESULTS: DCs derived from VKC patients were of a more mature phenotype than those from normal controls. However, these VKC DCs had reduced capability for induction of T cell proliferation compared with DCs from controls. CONCLUSION: The increased maturity of DCs in VKC patients correlates with the heightened immune responsiveness associated with this disorder. A number of mechanisms may underlie the impaired ability of DCs in atopy to stimulate T cell proliferation. This impairment of DC induction of T cell activation is likely to be one factor which contributes to the modified inflammatory response seen in VKC patients and the recognised susceptibility of these patients to viral infection.


Subject(s)
Conjunctivitis, Allergic/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , T-Lymphocytes/immunology , Antibodies, Monoclonal/immunology , Conjunctivitis, Allergic/genetics , Donor Selection , Flow Cytometry , Humans , Lymphocyte Activation , Phenotype , T-Lymphocytes/cytology
14.
Int Immunol ; 22(2): 113-28, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20173038

ABSTRACT

Chemokines play important regulatory roles in immunity, but their contributions to mast cell function remain poorly understood. We examined the effects of FcepsilonRI-chemokine receptor (CCR) 1 co-stimulation on receptor localization and cellular morphology of bone marrow-derived mast cells. Whereas FcepsilonRI and CCR1 co-localized at the plasma membrane in unsensitized cells, sensitization with IgE promoted internalization of CCR1 molecules. Co-stimulation of FcepsilonRI and CCR1 with antigen and macrophage inflammatory protein-1alpha was more effective than FcepsilonRI stimulation alone in causing leading edge formation, flattened morphology, membrane ruffles and ganglioside (GM1(+)) lipid mediator release. Co-stimulation resulted in phalloidin-positive cytoneme-like cellular extensions, also known as tunneling nanotubes, which originated at points of calcium accumulation. This is the first report of cytoneme formation by mast cells. To determine the importance of lipid rafts for mast cell function, the cells were cholesterol depleted. Cholesterol depletion enhanced degranulation in resting, sensitized and co-stimulated cells, but not in FcepsilonRI-cross-linked cells, and inhibited formation of filamentous actin(+) cytonemes but not GM1(+) cytonemes. Treatment with latrunculin A to sequester globular-actin abolished cytoneme formation. The cytonemes may participate in intercellular communication during allergic and inflammatory responses, and their presence in the co-stimulated mast cells suggests new roles for CCRs in immunopathology.


Subject(s)
Actins/metabolism , Cell Communication , Mast Cells/metabolism , Membrane Microdomains/metabolism , Receptors, CCR1/metabolism , Receptors, IgE/metabolism , Animals , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Calcium Signaling , Cell Communication/drug effects , Cell Shape , Cells, Cultured , Chemokine CCL3/metabolism , Cholesterol/deficiency , Endocytosis , Female , G(M1) Ganglioside/metabolism , Mast Cells/drug effects , Mast Cells/immunology , Membrane Microdomains/drug effects , Membrane Microdomains/immunology , Mice , Mice, Inbred BALB C , Protein Transport , Rats , Receptors, CCR1/genetics , Recombinant Proteins/metabolism , Thiazolidines/pharmacology , Time Factors , Transfection
15.
Adv Exp Med Biol ; 709: 43-52, 2010.
Article in English | MEDLINE | ID: mdl-21618886

ABSTRACT

Ocular allergy is a disorder affecting increasing numbers of individuals worldwide. Among the inflammatory mediators that contribute to ocular allergy, histamine is perhaps the best characterized. This monoamine is released by sensitized mast cells upon exposure to allergen and causes symptoms such as redness and tearing. Histamine may also recruit immune cells that can cause long-term damage to ocular surfaces. In this chapter we will discuss the known functions of histamine and histamine receptors in ocular allergy and will describe promising therapies targeting the histamine-signaling pathway.


Subject(s)
Conjunctivitis, Allergic/immunology , Eye/immunology , Histamine/immunology , Animals , Conjunctiva/immunology , Conjunctivitis, Allergic/drug therapy , Histamine Antagonists/therapeutic use , Humans , Hypersensitivity/immunology , Receptors, Histamine/immunology , Signal Transduction/immunology
16.
J Autoimmun ; 33(3-4): 247-54, 2009.
Article in English | MEDLINE | ID: mdl-19846275

ABSTRACT

Autoantibody production is associated with a variety of ocular disorders, including autoimmune retinopathy (AIR) and age-related macular degeneration (AMD). A breakdown of immunologic tolerance (ocular immune privilege), including the blood-retinal barrier, anti-immune and anti-inflammatory proteins, and anterior chamber-associated immune deviation may play important roles in these disorders. Although the exact triggers for ocular autoimmunity are unknown, autoimmune targeting of retinal tissue is clearly associated with and may contribute to the pathogenesis of both AIR and AMD. Autoantibody production has long been associated with AIR, a collection of disorders that includes cancer-associated retinopathy, melanoma-associated retinopathy and non-paraneoplastic autoimmune retinopathy. A growing body of evidence indicates that AMD pathogenesis, too, involves ocular inflammation and autoimmunity. Identification and quantification of autoantibodies produced in patients with AIR and AMD may assist with diagnosis, prognosis, and choice of treatments. Animal models that allow investigation of ocular autoimmunity will also be needed to better understand the disease processes and to develop novel therapies. In this review we discuss ocular immune privilege and potential mechanisms of autoimmunity in the eye. We describe how autoimmunity relates to the pathogenesis of AIR and AMD. We explain how the antigen microarray technique is used to detect autoantibodies in patient serum samples, and discuss how current animal models for AMD can be used to investigate autoimmune pathogenesis. Finally, we outline unanswered questions and exciting areas of future study related to autoimmune retinal degeneration.


Subject(s)
Autoimmunity , Blood-Retinal Barrier/immunology , Macular Degeneration/immunology , Retinal Diseases/immunology , Animals , Autoantibodies/blood , Blood-Retinal Barrier/metabolism , Disease Models, Animal , Humans , Immune Tolerance/immunology , Protein Array Analysis , Retina/immunology , Retina/pathology
17.
J Allergy Clin Immunol ; 124(4): 827-33.e2, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19660804

ABSTRACT

BACKGROUND: Allergic conjunctivitis is characterized by allergen-specific IgE in the serum and infiltration of eosinophils into the conjunctiva. The role of IgE and mast cells in allergic conjunctivitis is largely unknown, however. OBJECTIVES: We investigated the importance of conjunctival mast cells in a murine model of IgE-mediated allergic conjunctivitis. METHODS: IgE-mediated allergic conjunctivitis was initiated in C57BL/6-Kit(+/+) wild-type mice, mast cell-deficient Kit(W-sh/W-sh) mice, and Kit(W-sh/W-sh) mice that had been subconjunctivally or systemically engrafted with bone marrow-derived, cultured mast cells (BMCMCs) from Kit(+/+) wild-type mice, and clinical symptoms and infiltration of eosinophil of the eyes were evaluated. Total numbers of mast cells in the conjunctiva were counted, and the phenotypes of these cells were characterized by means of immunostaining and PCR analysis of murine mast cell proteases. RESULTS: No mast cells were detected in the conjunctiva or eyelid dermis of adult Kit(W-sh/W-sh) mice. Subconjunctival injection of BMCMCs resulted in local mast cell reconstitution, with the numbers of reconstituted mast cells in the conjunctiva and eyelid dermis comparable with those observed in wild-type Kit(+/+) littermates. Reconstituted and naive conjunctival mast cells expressed proteases ascribed to connective tissue-type mast cells but not mucosal mast cells. Passive transfer of ragweed-specific IgE followed by antigen challenge resulted in both early-phase clinical symptoms and late-phase eosinophilic inflammation in Kit(+/+) mice. These responses, which were significantly decreased in Kit(W-sh/W-sh) mice, were restored on reconstitution of the conjunctival mast cell population. CONCLUSIONS: These results suggest a direct contribution of IgE-activated mast cells to both the early-phase reaction and late-phase inflammation during ocular allergy.


Subject(s)
Conjunctivitis, Allergic/immunology , Eosinophils/immunology , Immunoglobulin E/immunology , Mast Cells/immunology , Adoptive Transfer , Animals , Conjunctivitis, Allergic/metabolism , Conjunctivitis, Allergic/pathology , Disease Models, Animal , Eosinophils/metabolism , Eye/immunology , Eye/pathology , Immunoglobulin E/metabolism , Mast Cells/metabolism , Mice , Mice, Inbred C57BL
18.
Int Immunol ; 21(8): 991-1001, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19592420

ABSTRACT

Chemokine receptors (CCRs) are important co-stimulatory molecules found on many blood cells and associated with various diseases. The expression and function of CCRs on mast cells has been quite controversial. In this study, we report for the first time that murine bone marrow-derived mast cells (BMMC) express messenger RNA and protein for CCR1. BMMC cultured in the presence of murine recombinant stem cell factor and murine IL-3 expressed CCR1 after 5-6 weeks. We also report for the first time that mBMMC(CCR1+) cells endogenously express neurokinin receptor-1 and intercellular adhesion molecule-1. To examine the activity of CCR1 on these BMMC, we simultaneously stimulated two receptors: CCR1 by its ligand macrophage inflammatory protein-1alpha and the IgE receptor FcepsilonRI by antigen cross-linking. We found that co-stimulation enhanced BMMC degranulation compared with FcepsilonRI stimulation alone, as assessed by beta-hexosaminidase activity (85 versus 54%, P < 0.0001) and Ca(2+) influx (223 versus 183 nM, P < 0.05). We also observed significant increases in mast cell secretion of key growth factors, cytokines and chemokine mediators upon CCR1-FcepsilonRI co-stimulation. These factors include transforming growth factor beta-1, tumor necrosis factor-alpha and the cytokine IL-6. Taken together, our data indicate that CCR1 plays a key role in BMMC function. These findings contribute to our understanding of mechanisms for immune cell trafficking during inflammation.


Subject(s)
Bone Marrow Cells/metabolism , Interleukin-6/metabolism , Mast Cells/metabolism , Receptors, CCR1/biosynthesis , Transforming Growth Factor beta1/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Cells, Cultured , Female , Intercellular Adhesion Molecule-1/metabolism , Mice , Mice, Inbred BALB C , Receptors, CCR1/genetics , Receptors, CCR1/metabolism , Receptors, IgE/metabolism , Receptors, Neurokinin-1/metabolism , Signal Transduction
19.
J Pediatr Hematol Oncol ; 31(3): 209-14, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19262251

ABSTRACT

Retinoblastoma (RB) is the commonest primary intraocular tumor in children. Overexpression of the high mobility group (HMG) A2 protein has been observed in a variety of malignant tumors and often correlates with poor prognosis. We studied the expression of HMGA2 in primary tumor samples and correlated with clinicopathologic features such as invasion, differentiation, and laterality of the tumors. Among 64 tumors, there were 29 tumors with invasion of the optic nerve, choroid, and/or orbit and 35 tumors without invasion. HMGA2 immunoreactivity was evaluated on archival paraffin sections and the results confirmed by Western blotting on 12 fresh tumor samples. Among 29 tumors with invasion, HMGA2 was strongly positive (++) in 10 tumors, moderately positive (+) in 11 tumors. Among 35 tumors without invasion, HMGA2 was strongly positive (++) in 6 tumors, moderately positive (+) in 6 tumors. Tumors with invasion showed significantly higher expression of HMGA2 compared with tumors without invasion (P<0.01). Non-neoplastic retina was negative for HMGA2. There was no correlation between HMGA2 expression and differentiation/laterality. Western blotting revealed that 7 tumors were strongly positive, 2 were moderately positive, and 1 was faintly positive for HMGA2. Our study has demonstrated the HMGA2 expression in a large cohort of primary retinoblastoma tumors and its correlation with invasiveness.


Subject(s)
HMGA2 Protein/biosynthesis , Retinal Neoplasms/metabolism , Retinal Neoplasms/pathology , Retinoblastoma/metabolism , Retinoblastoma/pathology , Biomarkers, Tumor/analysis , Blotting, Western , Child, Preschool , Female , Humans , Immunohistochemistry , Infant , Male , Neoplasm Invasiveness , Prognosis
20.
Int Immunol ; 21(2): 187-201, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19147836

ABSTRACT

The immune response is regulated, in part, by effector cells whose activation requires multiple signals. For example, T cells require signals emanating from the T cell antigen receptor and co-stimulatory molecules for full activation. Here, we present evidence indicating that IgE-mediated hypersensitivity reactions in vivo also require cognate signals to activate mast cells. Immediate hypersensitivity reactions in the conjunctiva are ablated in mice deficient in eotaxin-1, despite normal numbers of tissue mast cells and levels of IgE. To further define the co-stimulatory signals mediated by chemokine receptor 3 (CCR3), an eotaxin-1 receptor, effects of CCR3 blockade were tested with an allergic conjunctivitis model and in ex vivo isolated connective tissue-type mast cells. Our results show that CCR3 blockade significantly suppresses allergen-mediated hypersensitivity reactions as well as IgE-mediated mast cell degranulation. We propose that a co-stimulatory axis by CCR3, mainly stimulated by eotaxin-1, is pivotal in mast cell-mediated hypersensitivity reactions.


Subject(s)
Allergens/metabolism , Chemokine CCL11/immunology , Conjunctivitis, Allergic/immunology , Conjunctivitis, Allergic/prevention & control , Glycoproteins/metabolism , Mast Cells/metabolism , Receptors, CCR3/antagonists & inhibitors , Receptors, CCR3/metabolism , Allergens/immunology , Animals , Cats , Cell Degranulation/immunology , Chemokine CCL11/metabolism , Conjunctiva/immunology , Conjunctiva/pathology , Conjunctivitis, Allergic/genetics , Glycoproteins/immunology , Immunoglobulin E/blood , Mast Cells/immunology , Mast Cells/pathology , Mice , Mice, Inbred BALB C , Mice, Knockout , Receptors, CCR3/genetics , Receptors, CCR3/immunology , Signal Transduction/genetics , Signal Transduction/immunology , Skin/immunology , Skin/pathology , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL
...